Literature DB >> 21763972

Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.

Patricia A Tang1, Michael M Vickers, Daniel Y C Heng.   

Abstract

The current treatment paradigm for metastatic renal cell carcinoma (RCC) includes agents that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. Because these agents have revolutionized RCC over the past five years, new clinical and molecular predictive and prognostic tools are required. These are potentially important for therapy selection, patient counseling, and clinical trial stratification. This review examines clinical prognostic models and molecular biomarkers in RCC.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21763972     DOI： 10.1016/j.hoc.2011.04.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  13 in total

1.  Renal tumors: diagnostic and prognostic biomarkers.

Authors:  Puay Hoon Tan; Liang Cheng; Nathalie Rioux-Leclercq; Maria J Merino; George Netto; Victor E Reuter; Steven S Shen; David J Grignon; Rodolfo Montironi; Lars Egevad; John R Srigley; Brett Delahunt; Holger Moch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

Review 2.  Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.

Authors:  Oscar Rodriguez Faba; Sabine D Brookman-May; Estefania Linares; Alberto Breda; Francesca Pisano; José Daniel Subiela; Francesco Sanguedolce; Maurizio Brausi; Joan Palou
Journal:  World J Urol       Date:  2017-07-12       Impact factor: 4.226

3.  Nonenhancing Component of Clear Cell Renal Cell Carcinoma on Computed Tomography Correlates With Tumor Necrosis and Stage and Serves as a Size-Independent Prognostic Biomarker.

Authors:  Firas S Ahmed; Oguz Akin; Hiram Shaish; Lyndon Luk; Xiaotao Guo; Hao Yang; Emily Zabor; Irina Ostrovnaya; A Ari Hakimi; Binsheng Zhao; Lawrence H Schwartz
Journal:  J Comput Assist Tomogr       Date:  2019 Jul/Aug       Impact factor: 1.826

Review 4.  Biomarkers in renal cancer.

Authors:  Holger Moch; John Srigley; Brett Delahunt; Rodolfo Montironi; Lars Egevad; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

5.  Integrative Analysis of Histopathological Images and Genomic Data Predicts Clear Cell Renal Cell Carcinoma Prognosis.

Authors:  Jun Cheng; Jie Zhang; Yatong Han; Xusheng Wang; Xiufen Ye; Yuebo Meng; Anil Parwani; Zhi Han; Qianjin Feng; Kun Huang
Journal:  Cancer Res       Date:  2017-11-01       Impact factor: 12.701

6.  Chromosomal imbalances revealed in primary renal cell carcinomas by comparative genomic hybridization.

Authors:  Xue-Ling Kang; Hong Zou; Li Juan Pang; Wen Hao Hu; Jin Zhao; Yan Qi; Chun-Xia Liu; Jian Ming Hu; Jing-Xia Tang; Hong An Li; Wei Hua Liang; Xiang-Lin Yuan; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

7.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2013-01-09       Impact factor: 41.316

Review 8.  The circadian clock and the hypoxic response pathway in kidney cancer.

Authors:  Gianluigi Mazzoccoli; Angelo De Cata; Ada Piepoli; Manlio Vinciguerra
Journal:  Tumour Biol       Date:  2013-08-14

9.  Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.

Authors:  Sakshi Gulati; Pierre Martinez; Tejal Joshi; Nicolai Juul Birkbak; Claudio R Santos; Andrew J Rowan; Lisa Pickering; Martin Gore; James Larkin; Zoltan Szallasi; Paul A Bates; Charles Swanton; Marco Gerlinger
Journal:  Eur Urol       Date:  2014-07-19       Impact factor: 20.096

10.  Uncontrolled Confounders May Lead to False or Overvalued Radiomics Signature: A Proof of Concept Using Survival Analysis in a Multicenter Cohort of Kidney Cancer.

Authors:  Lin Lu; Firas S Ahmed; Oguz Akin; Lyndon Luk; Xiaotao Guo; Hao Yang; Jin Yoon; A Aari Hakimi; Lawrence H Schwartz; Binsheng Zhao
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.